文字起こしMad Money w/ Jim Cramer 1/11/22　＄ZTS INTERVIEW

ジムクレイマーのMAD MONEYの文字起こしになります。米国株を英語学習を通じて投資したい方に向けて作りました。皆さんの反応を見て改善点や英語解説などい追加して行けたらと思います。とても有益な番組なのにジムの英語が難しくて悩んたのをきっかけにこのノートを作成しました。 聞き取れない部分もあるのでご了承ください。是非Podcastを聴きながら合わせてこのnoteをみれば、様々なアメリカ英語を聞くことでリスニング力を鍛えることが出来ると同時に、タイムリーな米国株投資情報を得ることができます。イイネ！と思った方は投げ銭いただけると嬉しいです。

https://podcasts.apple.com/jp/podcast/mad-money-w-jim-cramer/id147247199

‎Apple Podcast内のMad Money w/ Jim Cramer

0:31 My mission is simple to make you money. I'm here to level the playing field for all investors. There's always a bull market summer, and I promised help you find mad money starts now. Hey, I'm Cramer. Welcome to Mad Money. Welcome to America. Again, my friends trying to make us money. My job is not just to entertain you but dedicated to you. So call me at one 800 743 CNBC or tweet me at Jim Cramer. Sometimes, there's just too much good news to ignore. And that's how I explained today's rally. Dow gaining 183 points, s&p advancing point nine 2% Nasdaq jumping 1.41% Call coming from much lower levels. Now one of the most infuriating aspects of this market, at least for the last couple of weeks is that nothing seemed to matter except for bonds, bond yields go higher money managers? Well, they just hit the machines and they sell. They know you can't fight a market where rates have exploded higher. That's what they think. Right? And that's when the Wall Street playbook says you just got to sell everything don't even distinguish. But so back to the machines. These days, the playbook has been turned into what I call an algorithm. So when you get certain inputs, like rising rapidly rising long term rates, lots of funds automatically sell stocks, no matter what do they might not even be human involved in the decision. The bigger the fund, the less I think there is a human at the helm. I mean, that's how defined they are. And what they typically sell is the s&p 500, the entire bundle of 500 stocks, usually through what's called a commodity future. So no major stocks get left out because it's the asset class and want to bet against the portfolio managers who trade like this, don't pick and choose what they sell. They don't say boom, let's sell the s&p futures except for this 40 stocks, I think are actually pretty good. They just sell everything very wanted to distinguish why? Because they don't get paid enough to try to distinguish between the good and the bad. And in many ways individual stocks are just too small to matter. They regard stocks as commodities, they're like corn or soy, right? It's just a bunch of soybeans in a basket 500 rubber, they have no desire to pick that basket apart. It's too much work. They don't want the hassle of picking stocks. And they're trying to make a bet not against the individual companies, but about the class that our equities. Think about. How often do you hear big money managers come on TV and actually name the companies they dislike? Oh, no. For the most part, aside from some notable exceptions, like the ones who go on Scott Walker's halftime show, you just say this vague generalities about how stocks in general are overvalued. That's what we're speaking about stocks in general evades s&p 500 cost too much. Sure. There are times when these top down portfolio managers get a little more granular. They'll talk about sectors they don't like to text the oils to healthcare. But for the most part, the real famous ones, they run so much money, they can't make meaningful bets on individual stocks, the positions will be too big. That's why they only talk about the averages trying to pick stocks for them, like commodity investors betting on a particular stock of wheat. Now on day down days, like we had last week or yesterday before the turn the stocks as commodities analogy really does work. When the markets getting hammered pretty much everything trades together and feels like a waste of time to distinguish among the grains and start looking at grain and stock. That is General Mills that did well. Oh, the grain of stock that is a Clorox that was up Oh, but then you got to save yourself. What happens when bond yields actually go down as it did today. And the stock market finally catches his breath. What happens when Jay Powell comes to Capitol Hill for his confirmation hearing doesn't go in the anti inflation Warpath nothing about how we need lockstep rate hikes, some break inflation and might need for him or more. Instead, he says that we data dependent with all this because maybe once we get over COVID, there could be a a cool down inflation. And that's what happened today. And it made us want to see what is worth. We see the trees through the forest so to speak. And it turns out that while the forest was looking pretty terrible 4:25 are not healthy trees. That it makes sense to do some by so let me give you some concrete examples of what's been going on in the basket. As we just trade the stock at traded as a unit. versus going Morgan Stanley raised his price target for a company we all know called Amazon for 4040 200 spacey on something I felt pretty good and the number of engineers it has probably there's so many engineers working at Amazon and must have some other batch that could be worth fortunes as it is Morgan Stanley says Amazon gained a lot of North American retail market share and had a solid holiday season given them any individual retailers didn't have such good Christmas numbers because of Omicron. And yet the consumers flush, it makes a ton of sense. And Amazon must have had a terrific quarter. So now the stock is zooming. And I've got to tell you something, it is about time, this company at 3307 Up 2.4% is still 400 points below its high. Second apple. Alright, now we've had multiple research notes in the past few days that indicate Apple had a really good holiday season, not to mention excellent Chinese sales. But that kind of data hasn't mattered. Apple stock was getting dumped on with everything else. It's a part of the s&p and remember to many money managers. It's just a few kernels in a bushel bushel of corn right now one kernel, a lot of kernels, but it's still just a kernel. It finally mattered to though, and the stock had a nice bounce. It did, I'd say I I don't want to say it was against what the SP digs, the s&p went up. But let's just say when the s&p was still doing nothing, it started to go higher. It was a kernel of recognition. Third, right now, JP Morgan is having a gigantic healthcare conference. For the most part, these companies are having tremendous quarters over and over we've heard companies saying terrific things. It hasn't mattered, because even though the health care's got dragged down by indiscriminate selling, well, this is a huge sector and for nearly all the stocks to have good things to say. And race numbers should not be overlooked. But it was overlooked. That's kind of nuts. But again, they're part of a bushel. We like to wettest the pet and livestock care company long later in the show. But that wouldn't matter the whole big you get out like old Graham giant box and grain. You wouldn't see us from Adam. Or how about the twos to toxic name video gave last week too. They gave too. They told you a little gaming was doing it's right on the web. And our data centers are going and how fast they're the the sellings been and indicators. They indicate this quarter might be better than expected. It was completely Good. Then there's Andy's Lisa Sue good, gave you a terrific roadmap at CES last week that shows that things could be excellent for the chip maker for multiple years. It was driving me crazy. No one even seemed to even listen again to why the hedge fund so these stocks are just pieces of corn. And as soon as from any other on a day like today, though, those guys aren't control. Six, we all know boy, he's been in trouble, right? But today we learned that 737 Max are the numbers for 2021. They weren't that bad. Now, they're not a lot better than expected. But think about this travel comes back in the airlines team work capacity, they can see a big uptick in orders. So the stock goes up six bucks, but there could be much more to it, which is why we're holding for Chow because again, no one cared when this stuff came out when the market was still down and people yawn. Why? Because Boeing is part of the s&p. But when the interest rates come down Boeing bring to the floor. Of course, there will always be some companies that do disappoint. We've seen a bunch of retailers report weaker than expected numbers for December, the most important month of the year, by the way, but we're also hearing that January usually not important month but it's been a barber for many companies and the earnings estimates are being lifted for 2022 not cut because in the tours are so lean and there's no post Christmas promotion. Now if you're a huge portfolio manager only thinks that there's asset classes because anything more grand than that is too microscopic to matter, then maybe you don't care. The Costco had a fabulous month of G's been upgraded by multiple or CVS just pronounced much better than expected numbers. To these big time portfolio managers. People like me try to distinguish among the individual companies are a waste of time and are wasting their time. They see us as small thinkers, Lilliputians even looking for valuable quarts of oil and a 55 gallon drum. But you and the millions, hundreds of millions of people who don't trade stocks, like live cattle or soybean futures, it absolutely does matters. It matters. It should matter. It always will. The bottom line, when bonds finally go in the right direction. And Jay Powell stays thoughtful. We get ourselves a stock pickers market like we had today. You got to be ready for these because the stock market dies by the bond market soared. Can also prosper. David in Florida, David ujar. Jim Well, yeah, David. 9:09 So I want to so I'm a member of your Investing Club, and I realized how much I love Chevron. If I also want to ask you about Exxon 9:18 though I'm playing him and first I'm bigger in the club, David. We're getting ready to do some really exciting things including some videos. Now it is very difficult to distinguish Exxon from Chevron because they're considered to be both great companies now, Exxon was is a lot more troubled company. And it's been going up and Chevron's much less than its better growth. It's been going up. We own Chevron because we like the balance sheet. We like the dividend we like the buyback. Exxon has been troubled on the on the buyback. Well it's it's a Exxon has been balance sheet has been stretched. And one look at the dividend even a period for this amazing run from Chevron. Exxon is yielding 4.9 and Chevron is yielding 4.1 Even though Chevron has had just just shy Let's stick with Chevron. Justin in California, Justin. Jim, 10:05 greetings from sunny San Diego. Oh, good to have you. Here's the situation, I made an absolute bundle by getting in on Tesla early. And I'm thinking that right now might be a really good time to diversify. I'm a huge fan of the sector. And I'm wondering what would be your top five ad companies? Aside from Tesla? 10:29 Okay. Well, I mean, what I've been saying Just so we're clear is that Evie is a very, very crowded, crowded field. I mean, crowded, there are so many battery companies, so many companies that make this stuff within a battery. There's so many companies that are just kind of just out there making metals like MP. Um, so when I simplify things and just say, look on Tesla, they're the number one and if you want what's on the Comm, then do what we did natural herbs and by Ford, which has a Ferrari electrify group of fleet coming out next year, and it'll be more and more electrified. And I think that unlike most of the companies that have Evie vehicles, theirs are going to sell well. Sometimes there's just too much good news to ignore. And that gives you a stock pickers market. We look through the bushel and find what's great to own their money tonight. Healthcare's taking over the farm fresh off and companies presentations to JP Morgan healthcare conference, on getting the latest in health care for animals with the CEO of Zoetis, which is when we'd like for a long time, and is very inexpensive versus where was not that long ago. Then for a couple of weeks for the NASDAQ. Could today's bounce be a sign of what's to come? Or is it just a flash in the pan? I'm going off the charts find out and buy marine park today it's releasing data on one of its phase three treatments, and I'm getting the latest or the results with the company's top brass. So stay with Kramer. 11:54 Don't miss a second of Mad Money. Follow at Jim Cramer on Twitter. Have a question. Tweet, Cramer hashtag mad tweets, send Jim an email to Mad money@cnbc.com Or give us a call at one 807 43 CNBC miss something head to Mad money.cnbc.com CNBC is workforce Executive Council is a premier group of C suite Human Resources executives from leading companies across the country. It offers a members only portal and chat plus exclusive industry content. With access to Breaking News calls and digital networking experiences. The network and resources HR leaders need now applying to the workforce executive council at CNBC counsels.com/wec. 12:56 Now it's so many quality stocks are down big from their highs, you got to be ready to buy the good ones that work in this new environment. While there are a lot of losers that did deserve to get the boot. First Company babies that tossed out with the bathwater. Consider the case of one of our longtime favorite said 's awareness, which makes drugs vaccines and diagnostic equipment for both pets and livestock health care is not just for humans. Here's a stock that's been a fabulous long term performance came public at $26, roughly eight years ago, it's now about $212. But this thing was $249 Just a couple of weeks ago. So S has been crushed, along with so many other high quality growth names, even though it's got real products or real profits. Plus, if you're worried about a Fed mandated slowdown, this precisely kind of recession resistant Sacramento. Now the big JPMorgan health care conference, so I just told him very compelling story about its superior growth rate and superior margin expansion, fueled by the humanization of pets, we're gonna focus on that, and rising demand for meat from emerging market countries. I'm a believer, you know that since it came public? Don't take me. Let's see, keep with Kristin Peck. She's the CEO of Zoetis. You're more about her vision for the future. This back. Welcome back to Mad Money. 14:03 Well, thank you for having me, Jim. It is great to be back and certainly to be talking about our three favorite topics, pets and meat and the human animal bond. So thanks for having me. 14:12 Absolutely. Right now, last time I saw you as for the pandemic, and I think things have changed radically in the pet market, so to speak, in what had happened to pets up since people have been cooped up at home and what they do. How much has an impact is awareness that the level of care of pets and the number of pets that have been adopted has really skyrocket? 14:35 Absolutely, there has absolutely been a boom in the pet market and a few things are driving that. As you mentioned, more people are adopting more pets. More of us are staying home with our pets. So we're noticing every limb, every edge and every member but I think the really important long standing trend is who's adopting these pets, which is 50% of these pets are now adopted by millennials and Gen Z and they're much more involved in the care of their pets. They do a lot more research. And really, we see that as a trend that will continue to drive the companion animal market in years to come. 15:08 Now we use awareness products for our for our months. But I only know them as awareness because I know you. My wife knows them as high quality products. How do you distinguish between some lettuces products, and the others? Because your brand and your company spends a lot more in r&d? And as a lot more filming around it with many different kinds of diseases than all the other companies combined here? 15:33 It's a great question. I mean, from the veterinary space, I think, you know, vets know our products. It's really the science and the innovation that we drive. As you look at some of the biggest categories for us parasiticide, we have the only combination triple combination, fleet check, heartworm product in the US with trio, we look at DERM apoquel, cytopoint, you know, in Europe, our pain maps, which we're super excited about. But I really think we're investing a lot more to your point in doing direct to consumer advertising in the US and in markets around the world to build that brand awareness with a pet owner. So they know the value they're getting when they invest into what is products, 16:08 people who don't have pets might not know, but only a pet is expensive. Can Is there a price point where people can't meet members cash pay? So when you come up with your prices, you have to be thinking can people afford to do this? 16:23 Absolutely. It's a key part of how we look at it. And you know, it's we're not, you know, human health, there's third party payers, it's a self pay market. So as we're developing products, we have to be sure that we can really provide an innovative product that meets a medical need. And at a price point that makes sense for the pet owner. And you know, we've been able to launch monoclonal antibodies in the pet space in self pay, which many people thought we can never do both with cytopoint Certainly an edge. But with LaBella, and Valencia new monoclonal antibodies in Europe for arthritis pain, and really, we're seeing great uptake in these. So we've been able to bring quite disruptive innovation to the space at a price point that makes sense for the pet owner. 17:01 Now, when we talk last we started talking about the emerging markets in livestock. Why stocks going up in price? I mean, a lot of what we eat is going up in price. You've got a huge business in China, the increasing protein demand and consumption, can they afford to associate product there in order to be able to make it so that they have enough to eat? 17:23 Yeah, I mean, it's a really great question. As you look at emerging markets, as you mentioned in your intro, it's a big growth driver for us. It's so it is, but what's really interesting about it is it is more now like the companion animal and the livestock market historically, as you mentioned, China, you know, was mostly a livestock market with some companion animal. It's about 5050 for US and China. And you know, as you're looking at livestock with the outbreak of ASF, which I remember right before the pandemic, you and I had lunch, and you're discussing that, you know, you really saw, you know, obviously a real devastating impact. But you saw the growth of companion animal. And as they rebuild the herd in places like China, they're investing in bio secure new technologies. And they're really investing with our products where they're sure we have the science, the innovation and the outcomes they need. So, yes, I think as you look at some of these emerging markets, they are absolutely investing in the high quality products that we have. And so it is not just in livestock, but very interestingly, across companion animal as well. 18:17 One of the things I've never spoke with you about about fish is that a real cannot be a growing market, because obviously we all think that we've all learned in our diet shaft habit. 18:29 Absolutely. It's actually the fastest growing species. It may not be the largest, but it is the fastest growing species. And we're the number one company in aquaculture. Certainly the focus there is in SAM annoyed. So markets, like Norway, the UK, Chile, Canada. And really we're seeing increasing levels of fish, that we can actually now bring products to market. It's mostly focused on a vaccine market on prevention. So we see that as a huge growing space and one were heavily invested in. 18:56 Well, last thing, you've got that ongoing buyback, your stock is down very much down 12%. For the years, I've very rarely ever seen your stock this heart this high from the top. So you know this represents great value. 19:08 Well, we did get approval, as you noted for $3.5 billion share buyback plan. You know, at our board meeting, which we announced back in December, we've also been growing our dividend we announced a 30% growth there. But we have an incredibly strong balance sheet and extremely strong cash flow. And we can be flexible as we think about capital allocation. Our first focus is investing in our business, which you've seen us do that certainly in r&d, as you've mentioned, building capacity for the future demand that we've done direct to consumer, you know, really across the board, we can also certainly have the cash flow to invest in business development, as we announced our acquisition of Xerox last year that we're hoping to close this year. So you know, we are certainly really focused on capital allocation and we'll certainly be looking you know, over the coming months to make sure that we allocate that to continue to grow the company and provide value to our shareholders which As you know that we've beaten the s&p 500 for eight years now so it's 20:03 been a big presentation. Your presentation is excellent as I would only expect from you because you are a great steward of your company and want to thank Kristin peck the CEO of Zoetis for hardly ever get it this cheap. Thank you so much for coming on the show. Thanks so much, Jim. Great to be here. If you're looking for the kind of stock that you know, I backed into the very beginning, every time it's had a dip, it is actually the right to buy. This is one of those dips in Japanese back in. 20:36 Coming up, tackle the technicals Kramer takes a crack at the NASDAQ off the charts next. 20:52 After a brutal beat down over the last couple of weeks Tech bounced back nicely today. But we've had a lot of bounce and since we group peaked in November, which bounces real. The question is are we looking at a sustainable comeback that started yesterday afternoon, or merely a temporary rebound and then return to the abyss when the markets fall? Well, you know what I like to do I take my emotions out of the equation because it's easier for your feelings to lead you astray when in the averages are seesaw and the way that Aztecs and Cecily that means need to pull back with something more empirical, which is where the technicals come in. Remember, I don't agree with all the people who mentioned the technicals but I want you to see them yourself. So tonight we're going off the charts for the help of Kalyn broden she's a brilliant technician whose work you can now find Carolyn Baroda dot Academy and also Elliott Wave trader.net In order to get a better read on the NASDAQ 100. That's the 100 largest nonfinancial stocks in the NASDAQ composite. Now roughly a month ago broden warned us that this tech heavy index was headed for maker break moment. Take a look at the NASDAQ 100 daily chart. Okay. From four weeks ago, she told us that the MDX had a for support between 15 Four Oh, and 15 Five Oh, as long as that floor helped broken pick that this index could resume its uptrend, but for broke down she'd have to get a lot more bearish because the downside could be a normal. Now go into late December the NASDAQ 100 Quite a nice seasonal Santa Claus Rally, which is something that we remember we predicted with with Mr. Williams I went it's not that long ago, bouncing off the floor. But broden points out that even when it was rebounding, it never reached her full upside price target didn't get up here. Instead, it took a major turn for the worse there, one that her method did predict now remember, broden likes to measure past swings in the stock or an index and then run through the prism of Fibonacci numbers. That's a series of ratios discovered by the medieval godfather of mathematics that repeat endlessly in nature, pine cones, cones, shells, and for some reason, look, I'll never be able to explain it. But Fibonacci ratios do show up all over the stock market too. We don't need to know why it works. We only need to know that it's got surprising amount of predictive power. Like how she knew that if it didn't get here, it would go there, which was a total homerun call. When broad measures the duration of rally or decline and then applies these Fibonacci ratios. She can identify key dates where security is more likely to change this trajectory. NASDAQ 100 ran through a cluster of these Fibonacci timing cycles is very separate. And sure enough, the index peaked on the 28th before rolling over in the new year. Right. So what do we do now the rollovers accomplish yesterday the index template broke down below its critical floor of support on an intraday basis. Right there. Okay, although it finished the day above that level. At this point. broden says we need to look for the next important set of price parameters, along with any time includes that could help us predict when the brutal climb will run its course for the moment though even if it's today's rebound, she thinks an asset 100 isn't bad technical shape. And until that changes is vulnerable to another breakdown. That could be a lot more downside. Let's look at this next chart. This is a zoom out of a little of the daily chart broadens Fibonacci method had seven timing cycles coming due between yesterday and Thursday. Now get this. In other words, the same method that predicted a possible peak at the end of December. Alright, so Dillards should go down also predicted a possible low sometime this week. And that's exactly what happened yesterday. The MDX opening down big before finishing the session up very slightly. They only got some nice follow through today. So she thinks that there's a real possibility this tech move down could have legs that's really important. But for all we know, that just means it will last as long as the last tech we ventilate December, which Peter died after we can have NASDAQ 100 swiftly making new lows. How about price levels? Check out the NASDAQ 100 daily chart over the last while once broden knows that the recent break down here is already getting close in size. And here we take a look. We're going to be looking here close in size to some of the previous declines. So there we got these declines. You can see that the mine's been very severe when they happen. Now this is a concept known as symmetry. Big moves often repeat themselves the big ones. Okay. In a rational stock market, that would almost never happen, but this markets never been rational. You look at these red symmetry lines, based on the scale of the prior declines broken things to NASDAQ 100 could have a new floor support between 15,015 1062 There's the floor. It's worth pointing out that we bought him yesterday 15,000 More in 65 before rebounding nearly 4050 points that low, as long as that floor support holds. 25:32 broden thinks you can view this move at least as a tradable bounce. That's really important because a lot of people feel like okay, we just had everything. She's saying no, it could be tradable, could be more than this. However, even if the NASDAQ 100 is rebounding off, it's for sport. broden says you shouldn't assume that it will simply resume its long term uptrend and cruise to new all time highs. This index is currently below its 50 day moving average. That's the green line. See fell there. Can you see that the red and the blue blood foot and that is the kiss of death for most charters. And there are a lot of money managers out there who follow these charts, even if they weren't always admitted they would be selling this bounce today because of that. Meanwhile, Britain's favourite buyer sell triggered vols watching the five day exponential moving average and the 13 day exponential moving average. Or instead of counting days, you can watch 30 minute periods when the five day crosses below the 30 day that's one of the most reliable sell signals. And right now it's very much in effect for the NASDAQ 105 days blue 13 days red, obviously well below it. Still, she thinks this will be fairly could go further. That's what's important for us right now. And if there's real follow through, she might reassess and get more bush but you might want to use any additional strength as an opportunity to sell some tech but I would say define that as the unprofitable high price to sales multiple texts that have been put through the meat grinder that are just giving you dead cat bounces. Why? Because at the end is placed down below us for support. The downside could be a mess, but luckily for those stocks, remember you got to be select if you want to own tech in this environment. This market has no patience for the former high fliers that have no plans to turn a profit in the near future or even the medium future. These stocks were great inflate these they were terrific. But inflation was under control. And the Federal Reserve was committed to prop up the economy. But now that inflation is raging and the Feds getting ready to tighten these money losing tech stocks are not very much. Well, let's say they're not where you want to be. Instead, I recommend sticking with high quality tech names with great earnings or are profitable with perfect prospects like the ones we own for the child trust. Could you sell me bought yesterday the teeth of the sell off bottom line the charts turbid by cardboard broden says the tech lady NASDAQ 100 really was due for a bounce this week. And that bounce could continue. But don't get too comfortable. Don't get too attached to what she says. Because the overall technical picture remains ugly. Let's go to Chris in New York please, Chris. Jim boo. Yeah, we are Chris. What's up? 27:55 Good luck on Sunday. I think the Eagles have a real chance to win since my jets almost beat Tampa Bay two weeks. 28:01 You know, I agree with that. I think that you know the take that I think that we have very little loose what's going on? 28:09 Well, I was looking for an Asian stock to add to my portfolio. Except I may have invented this one at the wrong time. This internet company isn't just that it's a gaming and electronic payments company. Since last October, it looks as if the stock has fallen off a cliff into the sea. I think you know where I'm going with this. I have three buys into the stock already. And I want to make sure I'm not catching a falling knife. My question to you is on C limited ticker sec. What are your thoughts? All right, Chris, hold or run back? 28:45 To me, Chris, you're in the teeth of another country that just got put on a really bad COVID list from our country. And I think that country is terrific country and then we'll get things under control. But you don't know when but you don't cut and run from that when you by se it's an important situation. It's like Allah said it's like when for my Jabel dress. I did not receive Omicron or delta and se it's the same deal. You can hold it and buy more. But don't give up on it. That will be wrong. Okay. The charts as suggested by Carolyn Brode of the NASDAQ could go for a bounce back she's thinking that but she does not think it's going to take out the high so the overall tech picture remains ugly for her. Me I say if you'd be selective you'll be fine. What we're in Medan and putting my exclusive with bio Moran put the company behind several treatments for rare diseases be an opportunity for investors in 2022 There's been a lot of good news about it lately. I'm gonna kick them to the CEO and from gambling to streaming we are in the golden age of content. But is it too much content? I'm surveying the home entertainment space and lawyer calls rapid fire tonight's edition of the lightning round so stay with Kramer 30:03 We hear all the most exciting pharma and biotech stories that that JPMorgan healthcare conference that includes some long term loggers that could be ready to turn because they've got incredibly exciting news. Take biome, run pharmaceuticals, that's a biotech company that treats very rare diseases. For the last five years, the stock hasn't done that much. But yesterday, the Congress barber and told a terrific story about two products, their growth drug for children with the most common type type of dwarfism in humans that got approved last year. And I think something that we heard about a long time ago on the show, but could finally be here. And that isn't hemophilia treatment that could get approved later this year, we got some very strong data on the hemophilia drug in response to stock more than 5% today, but that doesn't seem commensurate to how important this drug is. Let's check in with JB enemies, the chairman, CEO of BioMarin get a better sense of where his company's headed. Mr. PMMA. Welcome back to Mad Money. 30:55 Thank you. Thank you, Jim. It's great to be back. Sorry that I cannot be there in person. Because of COVID. But, but it's wonderful to to be with you, even on a reboot basis. 31:07 Oh, thank you. It's great to see you, sir. I don't think people may be out of me because it is zoom. And maybe because that conference wasn't out. You weren't 1000s people listen to you. But you know, this is an unprecedented set of results that you have for him affiliate. This has been one that so many companies have tried and never succeeded. I think you I'm gonna give you the floor to tell people how hard it is. So I mean, in my lifetime, I've now I've seen company at the company fail, you have something? 31:34 Yes, we do. So the data that we communicate, it was basically as good as we could hope. We've demonstrated durable, consistent, beating controlling hemophilia patients. So this is our gene therapy product cue is transformational treatment for these patients that went from these patients that were an altered state of care, which is to introduce infusion every week of recombinant factor eight to control their meeting their disease they went from while being under Setup care from 4.6 Being episodes per week, per year to less than one. And they're there, the usage of factory infusions went down 98%. So, so this is these are pretty dramatic results that obviously we are very excited about. And I think this is extremely good news for the hemophilia community. 32:28 Now, let's understand I'm used to having extraordinary rare, smaller population drugs that you've done so well, for people, this actually has a little bit larger population. So I know you're not varying from your strategy, which is fantastic. But there are a lot of people's lives who are going to be made very, very different because a bomb ran on this. Oh, no, 32:47 that is correct. Because, you know, worldwide there, actually, that's excluding India and China, but in the world that we can access there. Around 100 feet 150,000 patients with haemophilia a 60% of them are severe. This is the population we are going to be addressed. Addressing initially. So this is going to have a pretty significant impact on the positive impact on the hemophilia community. 33:14 And what they've been using, as I know from people who haven't used this factory, you are 85%. It was just by 85%, demonstrating much greater superiority to the current standard of care. 33:28 Now he's correct. That is correct. Yes. So the way we designed the study. And by the way, this is the largest GDP study ever done in history. 134 patients, right. And 33:41 I just think that the standard of care will change by next year. If I'm right, everyone will go by Murrin stroke. 33:48 Wow. It might take a little longer than that. But we're ready for it. We have manufacturing capacity for 10,000 treatment patients for treating 10,000 patients per year. And we can increase from there if necessary. So so we've been preparing for this for years, and we are really excited. 34:05 In the meantime, you also had some some terrific dwarfism drug. I know that that's a broad rubric name. I don't want to confuse people. But the expectations here were good, you did better. And that's going to continue to have you give you that diversified base and revenue growth. It's been so true for shareholders. 34:23 Now, that we are we are currently launching another product called Vox algo for April Rhodesia, which is also the number one cause of human dwarfism. The addressable population because this would be a drive only for patients under the age of 18 is about 23 24,000 patients in the developed world. We priced that drug at about $250,000 per year. So they the addressable market here in terms of an actual is $3 billion market plus and we are the only approved product for this indication. And if we're going to be like this for many, many years to come, 35:02 well, look, I've got to congratulate you. I know years ago, you told me Look, we might have something for hemophilia. And I know that it's been intractable, difficult and a horrible disease. It looks like you've delivered more than I ever thought you could. I want to congratulate you javma, the chairman and CEO of BioMarin for an amazing new drug that I hope gets approved worldwide. Great to see you, sir. 35:24 Thanks, Jim. Great to be here. 35:26 If you ever known anyone who has suffered from this disease, you know that there really hasn't been anything good. And he came here many years ago and told us this could happen. It's happening in 2022. In the stocks not reacting appropriately. It should be up for that money back after the break. 35:47 Stick around 35:48 may make a suggestion I would still 35:50 go Lightning Round is coming up next. 36:00 It is. Of course one of those hidden services. Bye bye bye. And then the lightning rolls over. Are you ready skied Daniel? Jim in Texas, Jim? 36:14 Yeah. Hey, Jim. Thanks for all your help. Thank you. I bought the stock late last year with Mad Money. The idea was a more diversified pot play. The ticker is gr WG grow generation. 36:31 Okay, we simply said when that stock got into the 47 was that there wasn't much board there. We thought it was terrific. But we wanted to take the game. We felt the bulls make money bears make money and pigs well, they get slaughtered. And it's time to go and frankly, we've never looked back. Let's go to Adam in Indiana. Adam uya from the Hoosier State Jim Nice to have you. 36:55 I bought this stock last February when shipping stock containers rate started to really close stocks up over 100% But still the P E under six and dividend yield over 20% Should I add my position? ticker? SP LK 37:10 No, that's a bolt carrier. We don't like any of the bull carriers going oil tankers. They are too inconsistent and they have too often caught that to partake. So we're not involved. Let's go to Suzanne in New York. Suzanne. 37:24 Hello, Jim happy and healthy New Year to you and your family. 37:29 Xavier what's up? 37:30 I'm calling about our IV N That's Rivia N Of course, we paid 104 Right when after their IPO just wondering what your so I 37:41 just left. Amazon is committed to be angled by their what they have, but also wants to go away for months to sell it stock but it won't be able to do for a couple of months. I don't think the ravine setup is all that great. I'm sorry, but thanks for the kind words. Mike in Texas, Mike. 37:59 GM greetings from Houston I found a small cosmetic healthcare company. last quarterly report 50% year over year revenue growth 50% of the revenue is GAAP net income share price down about half from the November highs and P E ratio is now in the low 30s. What are your thoughts on in mode? 38:24 I don't know why that stock fell so much. I think that's a great opportunity. I think it was just one of those paid with bathwater names. I think that's what I expect our viewers to do is come up exactly with names like inmode I think it's a good call. Let's go to Joanne in Florida Joanne. 38:38 Yes. Hi, Jim. Thank you so much for taking my call, and welcome. And for that for the wonderful advice you provide. Oh, financial, the financial education you get to so many with your show and the Investing Club. Anyway, my stock is Rio Tinto I was looking for a good dividend payer with a low P E and decent earnings. And also I had read that they had just bought a lithium mine. I think in Argentina 39:06 book I've always favored owning real. I think it's just a great long term position. But remember, I also liked gold. And I think that this is a good mineral company over the multiple year time don't want to get over the short term and I think you got to go but let's go to Carrie and Colorado please Carrie. Hi. Hey, hey Gary. What's up? 39:26 Oh man, I'm so stoked to talk to you nothing. I am an invest club member. I'm so grateful for you and everything you've taught me and I'm interested in investing possibly in no vote here picker in VCR 39:39 you know, I do not understand no voucher is one of these companies. It is got a you know, I happen to think that people just turn on companies in general are in health care that nobody seems to want anymore. They have a revolutionary device that can be used for multiple different areas against cancer and I think it should be bought right here. It's down a great deal. I would I would do some buying How about interest in Maryland interest? Cramer man, how are you? I'm doing well. How are you? 40:08 I'm doing all right. I hope to get your not on the ticker symbol li see why they use me lithium ion battery second company? 40:15 Oh, man, those are you know, I would love to just say yes, I really would because it's down a lot. But this lithium batteries area is so controversial with so many players that I have to say wait a second. It is too speculative for me. Period. And I'm story Hassan and GA Assad. Cory my 40:37 ego. Don't think he's not right. My question is, what are your thoughts on at court incorporate? 40:46 Just plain perfect, Metal Bending company that I like other people may not like it. Why? Because it's just too boring. I think sometimes boring is good. I like your choice. Let's go to Jim in Nevada, please, Jim. 41:01 Hey, Jim, great to hear you, 41:03 man. Love your show. 41:05 Thank you. 41:07 Hey, I got a question for you. Virgin Galactic. I rode the wave last year from 20 up to I guess they sold Buck 56 and kind of washed it volatile all the way back down and I don't know where it's hovering now. So 41:23 you know, I never liked it. I saw it go up on a short squeeze. It's come back down a great deal. Maybe get a bounce but frankly the stock is just not for me wait just a second. And that leisure is the new version of the 41:38 lightning round is sponsored by TD Ameritrade comm and to which streaming platforms are you giving the time of day? Kramer makes sense of the battle for your eyes and ears next. Jim Cramer you're one of my heroes. 41:58 I look forward to your show every weeknight thank you so much for helping beginning investors like me when you 42:04 talk about the market. I just believe that you're spot on. Oh, I love it. Thank you so much every night we want you I have learned and earned 42:33 you're outta touch my baby. My poor discarded baby. I said baby, baby, baby, you're out of time. I know the Rolling Stones weren't singing about the state of the at home entertainment business in 2022 when they wrote that song a long time ago. But interesting is relevant today. Because I think at last, we might be out of time to watch more program. A few years ago when I asked Reed Hastings, the CEO of Netflix about his biggest competition. He didn't talk about other streaming services or TV stations, he said time will be the real competition. In other words, there won't be enough hours in a day to watch all programming you might like across all of these programs, and we were nowhere near that level. Fast forward to today. From the looks of everyone in the industry, cable companies, video game players streaming services, the coming Metaverse TV networks, we may have maxed out, we may have really reached a level where we're simply out of time. So what kind of shock even if we knew it was coming yesterday, Take Two Interactive announces its acquisition of Zynga a deal investors didn't seem to like because take two is a marquee video game company. Well, Zynga makes cheap little mobile games that really don't stack up to the beauty of Grand Theft Auto or Red Dead Redemption. However, mobile games are insanely popular with the on the go consumers outside the house. And even people who are multitasking just like how Activision is Candy Crush kids play pretty much everywhere you go. Mobile gaming expands the clock of video game usage, beyond what take to can deliver wire home. Then there's sports gambling, when you see the promotions, these online betting sites are offering you know millions of people must be watching these games on TV and watch them to the end to find out the final score. That translates again into fewer hours for other types of entertainment. I think the whole industry needs to come to grips with this. Earlier today when I was perusing the must be news items by John Ellis. I was struck by a little factoid. Gallup just took a poll that showed Americans read an average of 12.6 books a year. That's the smallest number they've measured since 1990. Now how much more connect go down to free up more time to watch entertainment companies and their programming can they really get more of your time? I'm not sure. We know that when the Omicron stream finishes burning fruits and country will finally feel immunized not protected from hospitalization, but actually immunized and immunized person is less likely to spend time at home less fearful. In fact, that person is liable to travel experiential, which again means fewer hours for at home entertainment. Me law at home is the competition getting serious about grabbing their own slice of the clock case in point, Mary Kingstown Alright, we just downloaded this excellent program. It's paramount plus, by the way for this year. More says me looks like we now have to watch something on Paramount plus to get our money's worth. Hmm, why not? Now we are cord cutters. But our students are starting to get mighty big and we don't want to get nothing for something. I think we're finally at that inflection point that Reed Hastings talked about that inflection point where there just isn't enough time to consume even a fraction of the media you might want. And it's not like we can create more time. Now I'm sure we're in a situation where there still can be excellent subscriber growth from Netflix internationally, and I do like the company, but I don't want to bet on their domestic business anymore. Not with this plethora of programming. Sure, some may be out of touch. But just as definitely, we're all out of time. I like to say there's always more market somewhere to find it just for you right here on Mad Money. I'm Jim Cramer. See you tomorrow.